Navigation Links
Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Date:12/1/2008

Presentation to Highlight Results of Ocular Neuroprotection Candidate

FREMONT, Calif., Dec. 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its Chief Operating Officer, Dr. Rami Skaliter is scheduled to present results on the Company's ocular neuroprotection candidate at the 20th Annual Piper Jaffray Health Care Conference to be held December 2-3, 2008 at the New York Palace in New York City.

                       Event: 20th Annual Piper Jaffray Health Care Conference
                       Date:  Tuesday, December 2, 2008
                       Time:  11:30 am ET

As previously announced, the ocular neuroprotection candidate is the Company's first RNAi drug candidate having a novel, proprietary structure covered by Quark's intellectual property. Data has validated its neuroprotective effects on dying retinal ganglion cells, a cause of blindness and glaucoma.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pf
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Dr. Kwame Bawuah ... the workshop with an admonition to the youth to ... in life. He also advised the youth to stay ... sex. He said, “This workshop will afford you the ... you to withstand the storms in your career path.” ...
(Date:7/24/2014)... 24, 2014 The first-ever successful isolation ... patient’s blood has been achieved by NFCR-supported scientist Daniel ... Hospital. This is an important milestone on the road ... the best treatment for each patient. , “Tumors ... often acquire new genetic features that make them resistant ...
(Date:7/24/2014)... the patient or their tumor more directly to ionizing ... damages the cancer cells irreparably. Unfortunately, such radiation is ... the site of the tumor, which is then at ... cancer. As such finding ways to protect the overlying ... Journal of Low Radiation, Faruck Lukmanul Hakkim of the ...
(Date:7/24/2014)... have uncovered a way the malaria parasite becomes ... Washington University School of Medicine in St. Louis, ... bacterial infections and tuberculosis. , The study appears ... Many organisms, including the parasite that causes malaria, ... play multiple roles in keeping organisms healthy, whether ...
(Date:7/24/2014)... Charlotte, NC (PRWEB) July 24, 2014 ... donated over $138,000 in sealant and anesthesia reversal ... ToothFairy® (NCOHF) to help save young smiles. The ... Sealant Kits and Oraverse® was distributed to America’s ... the U.S. with vital oral health services. The ...
Breaking Medicine News(10 mins):Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2
... responsible for a form of the herpes virus that causes ... causes purple skin blotches and can also attack the internal ... disease defenses but attacks those with weakened immune system as ... 8 was discovered six years ago. Almost 30% to 50% ...
... not reduce ,the risk of cardiac events ... disease (CAD). In the PHASE trial (Papworth ... women with angiographically proven coronary ,artery disease ... without cyclic norethisterone--or no hormone replacement therapy. ...
... Lunelle-a monthly injectable contraceptive pill has been approved by ... is more than 99 percent effective when women get ... release marketing the pill., ,Lunelle is an alternative ... months. It works Like many other birth control pills ...
... overall long-term survival rates in both men and women. Their ... ,Researchers studied survival rates based on a lung function ... the lung function test on a group of more than ... age from 20 to 89 years at enrollment. They have ...
... In some of the cancer patients the Tumors can't be ... using vitamin B12 that helps doctors locate hard to find ... vitamin B12. After three hours a gamma camera takes pictures ... cancer and he says that, "The cancer stands out as ...
... The American Heart Association announced it has revised ... of ,cardiovascular emergencies., ,Untrained bystanders and CPR-certified ... an unconscious person's pulse before administering chest compressions. ... breath, movement and response to stimulation as indicators. ...
Cached Medicine News:
(Date:7/24/2014)... -- Decision Resources Group finds that, for the treatment ... France , Germany , ... and the United Kingdom ) hold ... beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). ... first-line LABA/ICS FDC in the treatment of asthma with ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- "North America ... key market data on the North America Orthopedic Braces ... of US dollars, and volume (in units) and average ... , Knee Braces and Supports , Ankle ... , Upper Extremities Braces and Supports. ...
(Date:7/24/2014)... 24, 2014 Boston Children,s Hospital,s Global Pediatric ... will feature an "Innovation Tank" – a forum designed ... pitch their business or product solution to a panel ... on how to accelerate the innovation and bring it ... of Friday, October 31, will be moderated by ...
Breaking Medicine Technology:Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... 2011 /PRNewswire-Asia-FirstCall/ -- Financial Highlights for the ... increased 40.8% to $7.68 million Gross profit increased 30.1% to ... 14.2% to $3.90 million, representing a net margin of 50.8% ... Financial Highlights for the Six Months Ended June ...
... Mylan Inc. (Nasdaq: MYL ) today announced that ... Tablets, 10 mg. This product is the generic version of ... hyperplasia, or an enlarged prostate. Uroxatral® Tablets ... months ending June 30, 2011, according to IMS Health. ...
Cached Medicine Technology:Nutrastar Announces Second Quarter 2011 Financial Results 2Nutrastar Announces Second Quarter 2011 Financial Results 3Nutrastar Announces Second Quarter 2011 Financial Results 4Nutrastar Announces Second Quarter 2011 Financial Results 5Nutrastar Announces Second Quarter 2011 Financial Results 6Nutrastar Announces Second Quarter 2011 Financial Results 7Nutrastar Announces Second Quarter 2011 Financial Results 8Nutrastar Announces Second Quarter 2011 Financial Results 9Nutrastar Announces Second Quarter 2011 Financial Results 10Nutrastar Announces Second Quarter 2011 Financial Results 11
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: